**Question:** By binding RANKL with high affinity, which of the following drug reduces bone resorption

**Core Concept:** RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) is a protein that plays a crucial role in the activation of osteoclasts, which are responsible for bone resorption. Drugs that can bind to RANKL with high affinity can inhibit osteoclast activation and reduce bone resorption.

**Why the Correct Answer is Right:** Denosumab is a human monoclonal antibody that selectively binds to RANKL with high affinity. By doing so, it inhibits the interaction between RANKL and its receptor, RANK, on the surface of osteoclast precursors. This prevents the activation and differentiation of osteoclasts, ultimately reducing bone resorption.

**Why Each Wrong Option is Incorrect:**

A. Raloxifene is a selective estrogen receptor modulator (SERM) used for the treatment of osteoporosis. Although it can affect bone remodeling, it does not specifically bind to RANKL with high affinity, making it an incorrect choice.

B. Etidronate is a bisphosphonate used to treat osteoporosis. While it can inhibit osteoclasts, it does not bind to RANKL with high affinity, making it an incorrect choice.

C. Teriparatide is a synthetic peptide used for the treatment of osteoporosis. Although it affects bone remodeling, it does not bind to RANKL with high affinity, making it an incorrect choice.

D. Denosumab, as explained above, selectively binds to RANKL with high affinity, inhibiting osteoclast activation and reducing bone resorption. This makes it the correct answer.

**Clinical Pearl:**

Understanding the pharmacodynamics of drugs targeting bone resorption is crucial for managing various bone-related disorders like osteoporosis, Paget's disease, and multiple myeloma. Denosumab is a specific and effective therapeutic option for these conditions due to its high-affinity binding to RANKL, contrasting with the other options which target bone resorption but lack this specificity.